Balyasny Asset Management
LPCN icon

Balyasny Asset Management’s Lipocine LPCN Stock Holding History

Balyasny Asset Management’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-2,181
Closed -$57K – 1991
2018
Q1 		$57K Sell
2,181
-3,113
-59% -$86.7K ﹤0.01% 1858
2017
Q4 		$310K Buy
+5,294
New +$329K ﹤0.01% 1727

Other funds holding LPCN

JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Balyasny Asset Management's LPCN Position: Q2 2018 in Review

Balyasny Asset Management sold out of Lipocine (LPCN) in Q2 2018, closing a stake of 2,181 shares — an estimated $57K sold.

Balyasny Asset Management first reported a position in LPCN in Q4 2017 and held it in 2 quarters. The position peaked at $310K in Q4 2017. 30 funds tracked by Wall St. Rank hold LPCN as of Q2 2018.

  • Balyasny Asset Management reported no remaining Lipocine position as of Q2 2018 after selling out during the quarter.
  • Balyasny Asset Management sold 2,181 Lipocine shares in Q2 2018, an estimated $57K.
  • Balyasny Asset Management first reported a position in Lipocine in Q4 2017 and held it in 2 quarters.
  • Balyasny Asset Management's Lipocine position peaked at $310K in Q4 2017.
  • 30 funds tracked by Wall St. Rank held Lipocine as of Q2 2018.

Based on Balyasny Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.